Apimeds Pharmaceuticals Us, INC S-1 registration statements

Apimeds Pharmaceuticals US, Inc. is moving forward with its initial public offering, as indicated by the filing of Amendment No. 7 to its Form S-1 registration statement.

Apimeds Pharmaceuticals US, Inc. files for an initial public offering aiming to raise $16.1 million to fund clinical trials for its bee venom-based therapy, Apitox, targeting osteoarthritis and multiple sclerosis.

Apimeds Pharmaceuticals US, Inc. is seeking to list its common stock on the NYSE American through a $14.4 million initial public offering.

Apimeds Pharmaceuticals US, Inc. has filed an amendment to its S-1 registration statement, indicating progress towards its initial public offering and plans to list on the NYSE American under the symbol APUS.

Apimeds Pharmaceuticals US, Inc. has filed an amendment to its S-1 registration statement for a firm commitment initial public offering of common stock, aiming to raise capital for clinical trials and operations.

Apimeds Pharmaceuticals US, Inc. has filed an amendment to its registration statement for an initial public offering of its common stock, aiming to raise capital for clinical trials and operations.

Apimeds Pharmaceuticals US, Inc. is seeking to go public to fund clinical trials for its bee venom-based therapy, Apitox, targeting osteoarthritis and multiple sclerosis symptoms.

Apimeds Pharmaceuticals US, Inc. has filed an S-1 registration statement for an initial public offering to fund the clinical development of Apitox, a bee venom-based treatment for osteoarthritis and multiple sclerosis.